Keros Therapeutics (KROS) Net Income towards Common Stockholders: 2019-2025
Historic Net Income towards Common Stockholders for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$7.3 million.
- Keros Therapeutics' Net Income towards Common Stockholders rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 135.50%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
- Latest data reveals that Keros Therapeutics reported Net Income towards Common Stockholders of -$7.3 million as of Q3 2025, which was up 76.28% from -$30.7 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Net Income towards Common Stockholders registered a high of $148.5 million during Q1 2025, and its lowest value of -$53.0 million during Q3 2024.
- Its 3-year average for Net Income towards Common Stockholders is -$20.9 million, with a median of -$39.4 million in 2023.
- In the last 5 years, Keros Therapeutics' Net Income towards Common Stockholders plummeted by 328.21% in 2022 and then spiked by 444.32% in 2025.
- Over the past 5 years, Keros Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$6.9 million in 2021, then tumbled by 328.21% to -$29.7 million in 2022, then tumbled by 35.42% to -$40.2 million in 2023, then decreased by 14.37% to -$46.0 million in 2024, then spiked by 86.25% to -$7.3 million in 2025.
- Its last three reported values are -$7.3 million in Q3 2025, -$30.7 million for Q2 2025, and $148.5 million during Q1 2025.